ArticleOncotarget2018
Full in-frame exon 3 skipping of
Registry-linked trialOpen access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01689584 (Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling), which is not on this map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers.International journal of molecular sciences · 2026Review
- Decoding the Transcriptional Complexity of the Human BRCA2 DNA Repair Gene Using Hybrid-seq.Biochemical genetics · 2026Article
- RNA Panel Sequencing Is an Effective Tool to Help Classify Splice Variants for Clinical Oncogenetic Diagnosis.Human mutation · 2024Article
- Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach.Human mutation · 2022Article
- Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation ofBiomedicines · 2022Article
- Value of the loss of heterozygosity to BRCA1 variant classification.NPJ breast cancer · 2022Article
- Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.American journal of human genetics · 2021Article
- Intrinsic Disorder and Phosphorylation in BRCA2 Facilitate Tight Regulation of Multiple Conserved Binding Events.Biomolecules · 2021Review
- 5' Region Large Genomic Rearrangements in theCancers · 2021Article
- Article
- A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2.Molecular biology reports · 2021Article
- Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by UsingCancer research · 2020Article
- Review
- Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma.Frontiers in genetics · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 14 institutions in 5 countries.
Sandrine M CaputoInstitut Curie, Service de Génétique, Paris, France.
Mélanie LéoneUnité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France.
Francesca DamiolaCentre Léon Bérard, Lyon, France.
Asa EhlenInstitut Curie, PSL Research University, CNRS UMR3348, Orsay, France.
Aura CarreiraInstitut Curie, PSL Research University, CNRS UMR3348, Orsay, France.
Pascaline GaidratInserm-U1245, UNIROUEN, Normandie University, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
Alexandra MartinsInserm-U1245, UNIROUEN, Normandie University, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
Rita D BrandãoMaastricht University, Maastricht, Netherlands.
Ana PeixotoDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Ana VegaDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Claude HoudayerInstitut Curie, Service de Génétique, Paris, France.
Capucine DelnatteService de Génétique médicale, CHU Nantes, Nantes, France.
Myriam BronnerService de Génétique, CHU Nancy Brabois, Nancy, France.
Danièle MullerLaboratoire d'Oncogénétique, Centre Paul Strauss, Strasbourg, France.
Laurent CasteraLaboratoire de biologie et de génétique du cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de Médecine Personnalisée, Caen, France.
Marine Guillaud-BatailleInstitut Gustave Roussy, Villejuif, France.
Inge SøkildeSection of Molecular Diagnostics, Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
Nancy UhrhammerLaboratoire de Biologie Médicale, CLCC Jean Perrin, Clermont-Ferrand, France.
Sophie DemontetyInstitut Curie, Service de Génétique, Paris, France.
Hélène TubeufInserm-U1245, UNIROUEN, Normandie University, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
Gaïa CastelainInserm-U1245, UNIROUEN, Normandie University, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
French COVAR group collaborators
Uffe Birk JensenDepartment of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
Ambre PetitalotInstitut Curie, Service de Génétique, Paris, France.
Sophie KriegerLaboratoire de biologie et de génétique du cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de Médecine Personnalisée, Caen, France.
Cédrick LefolInstitut Curie, Service de Génétique, Paris, France.
Virginie MoncoutierInstitut Curie, Service de Génétique, Paris, France.
Nadia Boutry-KryzaUnité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France.
Henriette Roed NielsenDepartment of Clinical Genetics, Vejle Hospital, Odense, Denmark.
Olga SinilnikovaUnité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France.
Dominique Stoppa-LyonnetInstitut Curie, Service de Génétique, Paris, France.
Amanda B SpurdleGenetics and Comp utational Biology Division, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Australia.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Florence CouletLaboratoire d'Oncogénétique et d'Angiogénétique Moléculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Mads ThomassenDepartment of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Etienne RouleauInstitut Curie, Service de Génétique, Paris, France.
Inserm · FRDélégation Paris 5 · FRHospices Civils de Lyon · FRInstitut Curie · FRUniversité Paris-Sud · FRAalborg University Hospital · DKCentre Hospitalier Régional et Universitaire de Nancy · FROdense University Hospital · DKUniversidade do Porto · PTVejle Sygehus · DKAarhus University Hospital · DKCentre Jean Perrin · FRInstituto Português de Oncologia Francisco Gentil · PTMaastricht University · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germline pathogenic variants in the
Indexed as
BRCA2 exon3PALB2RNA splicing defectssplice donor sitevariants
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT01689584ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.